Key result
Review summarizes the pathophysiology of sleep disordered breathing in HCM and OSA treatment effects.
Why the study?
Sleep disordered breathing concurrently occurs with hypertrophic cardiomyopathy and propagates morbidity and mortality, but its pathophysiology and treatment effects in this population warrant review.
This review summarizes the pathophysiology and therapeutic implications of sleep disordered breathing in patients with hypertrophic cardiomyopathy.
May support OSA screening in HCM; leaves open need for RCTs on treatment effects.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and sleep disordered breathing (SDB) is a treatable risk factor that has been seen to occur concurrently, and is known to propagate mortality and morbidity in a number of cardiovascular disease states including heart failure, and indeed hypertrophic cardiomyopathy. In this review, we summarize past studies that explored the simultaneous occurrence of HCM and SDB, and the pathophysiology of SDB in relation to heart failure, arrhythmias, cardiac ischemia and pulmonary hypertension in HCM. The current therapeutic modalities, with the effect of obstructive sleep apnea (OSA) treatment on HCM, are then discussed along with potential future directions.
No takes yet. Share an insight, caveat, or question.
Venkataraman et al. (2020) conducted a review in Hypertrophic cardiomyopathy and sleep disordered breathing. Obstructive sleep apnea treatment was evaluated. This review summarizes the pathophysiology of sleep disordered breathing in hypertrophic cardiomyopathy and discusses the effects of obstructive sleep apnea treatment on the condition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: